Ukko Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 62

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $45M

  • Investors
  • 21

Ukko General Information

Description

Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders. The company's technology uses artificial intelligence, immunology, computational biology, and protein engineering to make safe proteins that do not trigger an immune response, enabling physicians to prescribe to people products that are safe to consume.

Contact Information

Website
www.ukko.us
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2440 Tamalpais Street
  • Mountain View, CA 94043
  • United States
+1 (917)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
Corporate Office
  • 2440 Tamalpais Street
  • Mountain View, CA 94043
  • United States
+1 (917)

Ukko Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ukko Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 08-Jan-2026 $45M Completed Generating Revenue
6. Later Stage VC (Series A) 25-Jun-2025 Completed Generating Revenue
5. Later Stage VC 12-Jul-2024 Completed Generating Revenue
4. Debt - General 31-Dec-2022 Completed Generating Revenue
3. Later Stage VC 01-Jan-2022 Completed Generating Revenue
2. Later Stage VC (Series B2) 27-Jan-2021 $40M $47.7M Completed Generating Revenue
1. Early Stage VC (Series A) 24-Jul-2017 $7.7M $7.7M Completed Generating Revenue
To view Ukko’s complete valuation and funding history, request access »

Ukko Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-2
Series B-1
Series A 7,913,666 $0.000100 8% $1.24 $1.24 1x $1.24 14.96%
To view Ukko’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Ukko Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and glute
Drug Discovery
Mountain View, CA
62 As of 2023

New York, NY
 

Menlo Park, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ukko Competitors (2)

One of Ukko’s 2 competitors is Intrommune Therapeutics, a Venture Capital-Backed company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intrommune Therapeutics Venture Capital-Backed New York, NY
Alladapt Immunotherapeutics Formerly VC-backed Menlo Park, CA
You’re viewing 2 of 2 competitors. Get the full list »

Ukko Patents

  • 41

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 24

    Pending

  • Expiring in next 12 mo

Ukko Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026080920-A1 Mrna vaccine for peanut allergy treatment Pending 13-Oct-2024
AU-2023372823-A1 Compositions and methods for inducing desensitization to peanuts Pending 02-Nov-2022
EP-4612303-A1 Compositions and methods for inducing desensitization to peanuts Pending 02-Nov-2022
US-20260356896-A1 Compositions and methods for inducing desensitization to peanuts Pending 02-Nov-2022
WO-2024097713-A1 Compositions and methods for inducing desensitization to peanuts Inactive 02-Nov-2022 A61P37/08
To view Ukko’s complete patent history, request access »

Ukko Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ukko Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
AgFunder Venture Capital Minority
Continental Grain Company PE/Buyout Minority
Israel Biotech Fund Venture Capital Minority
Sanara Capital Venture Capital Minority
SNR Venture Capital Minority
You’re viewing 5 of 21 investors. Get the full list »

Ready to get started?

Request a free trial

Ukko FAQs

  • When was Ukko founded?

    Ukko was founded in 2016.

  • Where is Ukko headquartered?

    Ukko is headquartered in Mountain View, CA.

  • What is the size of Ukko?

    Ukko has 62 total employees.

  • What industry is Ukko in?

    Ukko’s primary industry is Drug Discovery.

  • Is Ukko a private or public company?

    Ukko is a Private company.

  • What is Ukko’s current revenue?

    The current revenue for Ukko is .

  • How much funding has Ukko raised over time?

    Ukko has raised $105M.

  • Who are Ukko’s investors?

    AgFunder, Continental Grain Company, Israel Biotech Fund, Sanara Capital, and SNR are 5 of 21 investors who have invested in Ukko.

  • Who are Ukko’s competitors?

    Intrommune Therapeutics and Alladapt Immunotherapeutics are competitors of Ukko.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process